Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles

Topic: Disease mechanisms in lab and animal studies

Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy. Two variants exist, referred to as GSK-3 alpha and GSK-3beta. In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3 alpha may regulate amyloid precursor protein processing and Abeta formation. The activities of both GSK-3 alpha and GSK-3beta are reduced by lithium, a well-tolerated drug used in humans to combat bipolar disorder. Here, we investigate the therapeutic efficacy of chronic lithium administration in aged 3xTg-AD mice that harbor both plaques and tangles. We found that lithium reduced tau phosphorylation but did not significantly alter the A beta load. Despite the reduction in phosphotau, lithium treatment did not improve deficits in working memory. Although other studies have investigated the effects of lithium on tau biochemistry, this study represents the first to address comprehensively its therapeutic potential on other critical aspects of AD including its effect on A beta and learning and memory. It remains to be determined from human clinical trials whether lithium treatment alone will improve the clinical outcome in AD patients. These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-A beta interventions.

Key findings

• In addition to the latter's well-described role in the phosphorylation of tau, reports also suggest that GSK-3 alpha may regulate amyloid precursor protein processing and Abeta formation.
• We found that lithium reduced tau phosphorylation but did not significantly alter the A beta load.
• These results, however, suggest that the most efficacious treatment will be combining lithium with other anti-A beta interventions.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.2353/ajpath.2007.061178
• PubMed: 17456772
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{caccamo2007-17456772,
  author  = {Caccamo, A. and Oddo, S. and Tran, L. X. and LaFerla, F. M.},
  title   = {{Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles}},
  journal = {The American journal of pathology},
  year    = {2007},
  doi     = {10.2353/ajpath.2007.061178},
  pmid    = {17456772},
  url     = {https://doi.org/10.2353/ajpath.2007.061178}
}

Related studies in Drug development

• Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model Brain pathology (Zurich, Switzerland) · 2014-02-12 · usefulness score 40/100
• Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease Biochemical and biophysical research communications · 2017-11-22 · usefulness score 38/100
• The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy Brain research · 2015-12-31 · usefulness score 41/100
• Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture Molecular neurodegeneration · 2017-05-19 · usefulness score 41/100
• Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease Journal of Alzheimer's disease : JAD · 2010-01-01 · usefulness score 36/100
• Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person Neuroscience letters · 1990-08-01 · usefulness score 45/100

Also tagged “phosphorylation”

387 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 387 tagged studies.

• CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease Brain : a journal of neurology · 2021-03-01 · usefulness score 43/100 · Biomarkers
• Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies The journal of prevention of Alzheimer's disease · 2017-01-01 · usefulness score 47/100 · Drug development
• Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies Expert opinion on investigational drugs · 2023-07-10 · usefulness score 41/100 · Drug development

Similar studies

• Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study 2009 · Drug development
• Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons 1997 · Drug development
• Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo 2005 · Drug development
• Lithium Trial in Alzheimer's Disease 2009 · Drug development
• Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3 1997 · Drug development
• Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation 2007 · Drug development

More on Drug development

• A review that covers this ground The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms Translational neurodegeneration · 2018-02-27 · usefulness score 48/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →